Press Release Jul 25 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
This approval is for a generic version of Jevtana Kit, specifically for a certain strength of the product. The company has not disclosed the launch date for the product due to confidentiality. The press release also mentions that Jevtana Kit generated significant annual sales in the previous year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from NATCO Pharma
- NATCO Announces Launch of First Generic Version of Nexavar (Sorafenib) Tablets in the U.S. Market
- Press Release Jun 01 2022
- NATCO records INR 2043.8 Crore consolidated revenue and INR 170.0 Crore of profit, after tax, for the year ended March 31' 2022
- NATCO Announces Launch of the First Generic Version of Revlimid (Lenalidomide capsules), in the U.S. market
- Press Release Mar 07 2022
Later from NATCO Pharma
- NATCO records INR 918.9 Crore consolidated revenue and INR 320.4 Crore of profit, after tax, for the First Quarter, FY2022-23
- Press Release Aug 17 2022
- Press Release Sep 19 2022
- Press Release Sep 24 2022
- Press Release Oct 04 2022
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma